Microalbuminuria and oxidative stress in essential hypertension

Journal of Internal Medicine

Volumn 255, Issue 5, 2004, Pages 588-594

  Giner, V ^a   Tormos, C ^b   Chaves, F J ^c   Saez G ^b   Redon J ^a,d  

^a Department of Biochemistry ^*  (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antioxidants; DNA damage; Hypertension; Microalbuminuria; Oxidative stress; Risk factors

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ANTIOXIDANT; CHOLESTEROL; GLUCOSE; GLUTATHIONE; MALONALDEHYDE; MITOCHONDRIAL DNA;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONONUCLEAR CELL; MULTIPLE REGRESSION; OXIDATIVE STRESS; PRIORITY JOURNAL; URINE;

EID: 2042439090     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01280.x     Document Type: Article

References (37)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356-60.
2. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 1988; 2: 530-3.
3. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.
4. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
5. Jager A, Kostense PJ, Ruhe HG et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 617-24.
6. Roest M, Banga JD, Janssen WM et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-61.
7. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
8. Redon J, Lozano JV, Liao Y, Miralles A, Baldo E, Cooper RS. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 801-7.
9. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39: 794-8.
10. Bianchi S, Bigazzi R, Valtriani C et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23(Pt 1): 681-7.
11. Redon J, Miralles A, Pascual JM, Baldo E, Garcia Robles R, Carmena R. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15: 79-86.
12. Pontremoli R, Sofia A, Tirotta A et al. The deletion/insertion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7: 2550-8.
13. Fernandez-Llama P, Poch E, Oriola J et al. Angiotensin converting enzyme I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998; 53: 1743-7.
14. Redon J, Chaves FJ, Liao YL et al. Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension. Hypertension 2000; 35: 490-5.
15. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension. The role of superoxide anion. Hypertension 1999; 34: 539-45.
16. Orie NN, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1999; 12: 1169-74.
17. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. Hypertension 2002; 39: 777-80.
18. Redon J, Oliva MR, Tormos MC et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-101.
19. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998; 31 (Pt 2): 189-93.
20. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation 2002; 105: 2107-11.
21. Brigelius R, Muckel C, Akerboom TPM, Sies H. Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relation to glutathione disulfides. Biochem Pharmacol 1983; 32: 2529-34.
22. Navarro J, Obrador E, Pellicer JA, Asensi M, Viña J, Estrela JM. Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. Free Radic Biol Med 1997; 22: 1203-9.
23. Muñiz P, Valls V, Perez-Broseta C et al. The role of 8-hydroxy-2′-deoxyguanosine in rifamycin-induced DNA damage. Free Radic Biol Med 1995; 18: 747-55.
24. Lerman LO, Nath KA, Rodriguez-Porcel M et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37(Pt 2): 541-6.
25. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension, Kidney Blood Press Res 2001; 24: 116-23.
26. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001; 37(Pt 2): 554-60.
27. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension?. Proc Natl Acad Sci 1991; 88: 10045-8.
28. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-9.
29. Fukui T, Ishizawa N, Rajagopalan S et al p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
30. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998; 54: 775-84.
31. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F. Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Human Genet 1992; 51: 197-205.
32. Redon J. Renal protection with antihypertensive drugs: insights from the microalbuminuria studies. J Hypertens 1998; 16: 2091-100.
33. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease. The role of oxidant stress. Cir Res 2000; 87: 840-4.
34. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender and ethnicity. Hypertension 2000; 36: 878-84.
35. Redon J, Baldo E, Lurbe E et al. Microalbuminuria, left ventricular mass and ambulatory blood pressure monitoring. Kidney Int 1996; 49(Suppl. 55): S81-4.
36. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20: 159-69.
37. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000; 26(Suppl. 4): 64-6.